C
RCKT icon

Covestor’s Rocket Pharmaceuticals RCKT Stock Holding History

Covestor’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
89
+63
+242% +$209 ﹤0.01% 2777
2026
Q1 		$0 Buy
26
+16
+160% +$64 ﹤0.01% 2682
2025
Q4 		$0 Hold
10
– – ﹤0.01% 2652
2025
Q3 		$0 Hold
10
– – ﹤0.01% 2673
2025
Q2 		$0 Sell
10
-2,709
-100% -$13.7K ﹤0.01% 2650
2025
Q1 		$18K Buy
2,719
+723
+36% +$7.14K 0.01% 1236
2024
Q4 		$25K Buy
1,996
+1,990
+33,167% +$30K 0.02% 1116
2024
Q3 		$0 Hold
6
– – ﹤0.01% 2652
2024
Q2 		$0 Hold
6
– – ﹤0.01% 2653
2024
Q1 		$0 Sell
6
-1
-14% -$28 ﹤0.01% 2638
2023
Q4 		$0 Buy
7
+2
+40% +$44 ﹤0.01% 2603
2023
Q3 		$0 Sell
5
-1
-17% -$18 ﹤0.01% 2595
2023
Q2 		$0 Hold
6
– – ﹤0.01% 2544
2023
Q1 		$0 Hold
6
– – ﹤0.01% 2469
2022
Q4 		$0 Sell
6
-1
-14% -$18 ﹤0.01% 2497
2022
Q3 		$0 Buy
+7
New +$109 ﹤0.01% 2471
2022
Q2 		– Sell
-13
Closed – – 2277
2022
Q1 		$0 Sell
13
-4
-24% -$69 ﹤0.01% 2379
2021
Q4 		$0 Buy
+17
New +$464 ﹤0.01% 2269

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Covestor's RCKT Position: Q2 2026 in Review

Covestor increased its Rocket Pharmaceuticals (RCKT) stake by 242% in Q2 2026, buying an estimated $209 and bringing the position to 89 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2777.

Covestor first reported a position in RCKT in Q4 2021 and has held it in 18 quarters since. The position peaked at $25K in Q4 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Covestor held 89 shares of Rocket Pharmaceuticals worth $0 as of Q2 2026.
  • Covestor bought 63 Rocket Pharmaceuticals shares in Q2 2026, an estimated $209.
  • Rocket Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2777 holding.
  • Covestor first reported a position in Rocket Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Covestor's Rocket Pharmaceuticals position peaked at $25K in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.